Bhagiradha Chemicals FY26: Growth Returns, but the Big Test is the Bheema Ramp-up

Bhagiradha Chemicals and Industries Limited closed FY26 with a sharper earnings profile than FY25, helped by a mix of better volumes, improved realizations, and operating leverage. On a consolidated basis, revenue from operations grew to 535.9 crores from 440.5 crores, a rise of 22 percent. EBITDA increased faster, up 55 percent to 57.1 crores, and profit after tax improved 31 percent to 18.2 crores.

The year also carried the weight of a large ongoing expansion cycle through the company’s wholly owned subsidiary, Bheema Fine Chemicals Private Limited. Management highlighted that higher depreciation and finance costs linked to the Bheema facility commissioning moderated profit growth, even as operating performance strengthened.

FY26 performance: realization recovery and operating leverage

In its FY26 highlights, the company attributed growth to both volume expansion and better value realizations. Management noted that volumes improved during the year, supported by better demand trends, while realizations also improved compared to the previous year. Some products moved closer to peak realization levels, though management expects recovery in certain products to be gradual.

On the cost side, the company indicated that raw material prices largely stabilized during the year. However, it also flagged sharp increases in crude-linked derivatives, attributing them to elevated crude prices linked to the West Asia conflict. Despite this mixed input environment, consolidated gross margin improved to 37.5 percent from 36.9 percent. EBITDA margin expanded meaningfully to 10.7 percent from 8.4 percent, supported by better realizations, improved capacity utilization, and lower power and fuel costs following the commencement of the solar project.

For FY26, the board recommended a final dividend of 0.15 per equity share of face value 1, subject to shareholder approval.

Financial summary

Q4FY26: strong revenue quarter and improved YoY profitability

In Q4FY26, consolidated revenue from operations rose to 158.1 crores versus 122.6 crores in Q4FY25 and 114.0 crores in Q3FY26. EBITDA for the quarter increased to 19.4 crores from 6.1 crores in Q4FY25. Profit after tax improved to 4.1 crores versus a loss of 0.9 crores in Q4FY25.

The company described the quarter as being supported by improved demand across key products, better pricing and a favorable product mix, and improved operating efficiency. It also said gross margins expanded by 717 basis points year on year, helped by better realizations and tapering raw material prices, excluding crude-linked derivatives.

Balance sheet and cash flows: expansion phase dynamics are visible

The consolidated balance sheet reflects the capex cycle. Total assets increased to 1,120.2 crores as of March 2026 from 933.2 crores as of March 2025. Property, plant and equipment rose sharply to 573.9 crores from 238.2 crores, while capital work in progress reduced to 94.2 crores from 287.8 crores, consistent with project capitalization.

Borrowings increased materially. Non-current borrowings rose to 153.1 crores from 30.0 crores, and current borrowings increased to 77.9 crores from 54.4 crores. Interest expense in the consolidated P and L increased to 17.5 crores in FY26 from 7.1 crores in FY25, while depreciation and amortization rose to 20.9 crores from 13.9 crores.

Cash flow statements further highlight the transition. Net cash from operating activities was 12.0 crores in FY26 versus negative 52.8 crores in FY25, helped by a smaller working capital outflow compared to the previous year. But investing cash outflow remained high at 160.2 crores in FY26, keeping overall free cash generation under pressure. Cash and cash equivalents declined to 16.4 crores at year end from 28.2 crores.

Strategy and scale-up: BCIL 2.0 is centered on the Bheema facility

The core strategic narrative is the shift into a larger manufacturing and product platform through Bheema Fine Chemicals. The company stated that Bheema Fine Chemicals Private Limited was incorporated in July 2020 and commenced commercial production on 27 March 2024. It also noted that FY26 included successful commencement of Phase I of the Bheema Fine project, with capitalization of about 400 crores.

The broader expansion program is described as total investments of more than 850 crores, including a 34-acre manufacturing facility in Karnataka, higher backward integration for new molecules, 9,002 MT installed capacity with two processing blocks, distributed control systems for automation, zero liquid discharge with complete water recycling, and a solar power plant aimed at reducing power costs.

The phasing is explicit.

The company also articulated an expected outcome from the expansion program: at full potential, it expects about 1.5x asset turn with improved margins.

Alongside capacity, management highlighted operating initiatives. The year saw upgrades of critical processes to improve efficiency, productivity, and reliability. The company also credited the solar project, commenced from April 2025, for reduced power and fuel costs and margin support.

Portfolio and customer base: diversification is gradual, but measurable

The presentation positions the company as an established player in the agrochemical space with a product basket spanning active ingredients, intermediates, and formulations. It also highlights a product portfolio capability count rising to 35 in FY26, and states that over the years it has launched more than 30 molecules at regular intervals through in-house R and D.

A key disclosure is that the share of the top five products in revenue has gradually reduced to 81 percent in FY26 from 85 percent in FY25, suggesting a slow broadening of the revenue base.

Customer metrics also point in the same direction. The company reported 149 customers in FY26, up from 130 in FY25, and stated that no single customer contributes more than 20 percent of sales. It also disclosed that the top five customers contributed 35 percent of revenue in FY26.

In the CEO commentary, management stated that during FY26 the company launched three new molecules and added 19 new customers, including five major customers. These metrics provide tangible evidence of portfolio and customer additions during the year.

What to track from here

Management’s forward-looking commentary emphasizes ramp-up. The CEO stated that the company expects a meaningful ramp-up in operations and is positioned to unlock its full revenue potential in FY27, alongside improved profitability. At the same time, management flagged external risks, particularly West Asia developments and potential impacts on global supply chains, freight costs, energy prices, and demand conditions.

For investors, the near-term picture is straightforward. FY26 shows improving operating metrics and margin recovery. But returns and cash flow conversion remain constrained by the heavy capex cycle, higher depreciation, and higher finance costs. The next phase of the story depends on how smoothly Bheema Phase 1B scales up over the stated 12 to 24 months and whether utilization and realizations rise enough to lift asset turnover and returns.

The company also maintains a stated revenue target of about 3.5x at consolidated levels over the next four to five years, supported by operating efficiency and a better margin profile. Execution against that ambition, alongside capital discipline as leverage rises, is likely to define the BCIL 2.0 outcome.